Have to keep R&D spends at 12% of revenue: Biocon's Kiran Mazumdar-Shaw

It's a high growth phase for us in Biocon Biologics: We crossed the Rs 1,500-crore mark in revenue for the first time this quarter. We will exit this year (FY23) at Rs 2,000-crore level

Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw

Sohini Das
Bengualru-based biotech firm Biocon has posted 35 per cent growth in Ebitda and 36 per cent growth in revenue in the Q3FY23. Its R&D spends went up 144 per cent to Rs 337 crore. In an interview with Sohini Das after the quarterly results, Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics, discusses growth plans for Viatris’ business, and why she wishes to keep R&D spends at 12 per cent of the top-line. Edited excerpts.

What’s your geographical expansion plan for the Viatris portfolio?

Viatris’ acquisition is a huge inflection point for our business, and this is going to be a transformational acquisition for Biocon. We would be among only a few fully integrated biosimilars companies globally. We are looking

First Published: Feb 15 2023 | 8:52 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com